A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

140

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

January 31, 2027

Conditions

Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy

Interventions

DRUG

HRS9531

HRS9531 will be administered by Subcutaneous injection

DRUG

Placebo

Matching Placebo will be administered by Subcutaneous injection

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY